Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1546-51. Epub 2007 Oct 29.

Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial.

Author information

1
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. ecohen@mcw.edu

Abstract

PURPOSE:

To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT).

METHODS AND MATERIALS:

A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT.

RESULTS:

The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome.

CONCLUSIONS:

There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.

PMID:
18029109
PMCID:
PMC2386758
DOI:
10.1016/j.ijrobp.2007.08.041
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center